CA2370296A1 - Amelioration de l'immunite induite par les lymphocytes t - Google Patents

Amelioration de l'immunite induite par les lymphocytes t Download PDF

Info

Publication number
CA2370296A1
CA2370296A1 CA002370296A CA2370296A CA2370296A1 CA 2370296 A1 CA2370296 A1 CA 2370296A1 CA 002370296 A CA002370296 A CA 002370296A CA 2370296 A CA2370296 A CA 2370296A CA 2370296 A1 CA2370296 A1 CA 2370296A1
Authority
CA
Canada
Prior art keywords
cells
thymus
subject
cell
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002370296A
Other languages
English (en)
Inventor
Richard Lennox Boyd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Norwood Immunology Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2370296A1 publication Critical patent/CA2370296A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une technique permettant de modifier la composition de la population de lymphocytes T ou d'augmenter le nombre de ceux-ci chez un sujet présentant une population ou une fonction de lymphocyte T anormale ou réduite, cette technique consistant à interrompre le signalement d'un stéroide sexuel au thymus d'un sujet. L'invention permet de traiter un sujet qui souffre d'une grande variété de maladies, par exemple, du cancer, d'une infection due au VIH, d'auto-immunité et d'hypersensibilité. Elle concerne, en outre, des techniques qui permettent d'améliorer la réponse immunitaire à un antigène, de traiter une maladie auto-immune, et de réduire une réaction de l'hôte contre le greffon dans une transplantation.
CA002370296A 1999-04-15 2000-04-17 Amelioration de l'immunite induite par les lymphocytes t Abandoned CA2370296A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP9778A AUPP977899A0 (en) 1999-04-15 1999-04-15 Improvement of t cell mediated immunity
AUPP9778 1999-04-15
PCT/AU2000/000329 WO2000062657A2 (fr) 1999-04-15 2000-04-17 Amelioration de l'immunite induite par les lymphocytes t

Publications (1)

Publication Number Publication Date
CA2370296A1 true CA2370296A1 (fr) 2000-10-26

Family

ID=3813977

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002370296A Abandoned CA2370296A1 (fr) 1999-04-15 2000-04-17 Amelioration de l'immunite induite par les lymphocytes t

Country Status (11)

Country Link
EP (1) EP1191975A4 (fr)
JP (1) JP2002542174A (fr)
KR (1) KR20020007371A (fr)
CN (1) CN100376288C (fr)
AU (2) AUPP977899A0 (fr)
BR (1) BR0009712A (fr)
CA (1) CA2370296A1 (fr)
HK (1) HK1046249A1 (fr)
NZ (1) NZ514975A (fr)
WO (1) WO2000062657A2 (fr)
ZA (1) ZA200108451B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20020086000A1 (en) * 1999-04-15 2002-07-04 Richard Boyd Stimulation of thymus for vaccination development
US20020071829A1 (en) * 1999-04-15 2002-06-13 Richard Boyd Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
CA2462046A1 (fr) * 2000-10-13 2002-04-18 Monash University Ameliorations de l'acceptation d'un greffon par manipulation de la regeneration thymique
AU2002216320C1 (en) * 2000-10-13 2008-04-03 Norwood Immunology Ltd Hematopoietic stem cell gene therapy
AU2002216323C1 (en) * 2000-10-13 2008-05-29 Norwood Immunology Ltd Disease prevention by reactivation of the thymus
AU2002218450A1 (en) * 2000-10-13 2002-04-22 Norwood Immunology Ltd Diagnostic indicator of thymic function
IL155413A0 (en) * 2000-10-13 2003-11-23 Univ Monash Hematopoietic stem cell gene therapy
AU2002225245C1 (en) * 2000-10-13 2008-07-17 Norwood Immunology Ltd Improvement of graft acceptance through manipulation of thymic regeneration
NZ525830A (en) * 2000-10-13 2005-07-29 Norwood Immunology Ltd Disease prevention by reactivation of the thymus
AU2001295270B2 (en) * 2000-10-13 2007-08-09 Norwood Immunology Ltd Treatment of T cell disorders
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
EP1620126A4 (fr) * 2003-04-18 2007-07-04 Norwood Immunology Ltd Prevention de maladies et vaccination avant reactivation thymique
RU2010114058A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение пептида в качестве терапевтического средства
BR112013033988B1 (pt) * 2011-07-01 2021-10-19 Beckman Coulter, Inc. Métodos de identificação e isolamento de uma ou mais populações de células t regulatórias imunossupressoras
CN103235135B (zh) * 2013-04-26 2015-02-04 史其新 一种用于表征外周调节性t细胞抑制活性的特征细胞群的检测方法及其应用
TWI820753B (zh) * 2016-11-11 2023-11-01 美商生命科學公司 使用人類間葉幹細胞以實現細胞性及體液性免疫的方法
AU2019225151A1 (en) * 2018-02-23 2020-08-20 Duke University Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants
US11819520B2 (en) 2018-02-23 2023-11-21 Duke University Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01500663A (ja) * 1986-08-18 1989-03-09 バンジ・（オーストラリア）・プロプライアタリー・リミテッド 動物の生殖機能の調節
AU634379B2 (en) * 1991-04-29 1993-02-18 Csl Limited Recombinant immunocastration vaccine

Also Published As

Publication number Publication date
CN1364093A (zh) 2002-08-14
EP1191975A4 (fr) 2005-05-25
HK1046249A1 (zh) 2003-01-03
AU3797700A (en) 2000-11-02
BR0009712A (pt) 2002-04-30
AUPP977899A0 (en) 1999-05-13
ZA200108451B (en) 2003-01-15
AU779067B2 (en) 2005-01-06
WO2000062657A2 (fr) 2000-10-26
KR20020007371A (ko) 2002-01-26
CN100376288C (zh) 2008-03-26
WO2000062657A3 (fr) 2001-01-11
NZ514975A (en) 2004-03-26
EP1191975A2 (fr) 2002-04-03
JP2002542174A (ja) 2002-12-10

Similar Documents

Publication Publication Date Title
AU779067B2 (en) Improvement of T cell mediated immunity
US20060188521A1 (en) Treatment of T cell disorders
CA2462758A1 (fr) Indicateur de diagnostic de la fonction thymique
US20040258672A1 (en) Graft acceptance through manipulation of thymic regeneration
CA2462681A1 (fr) Prevention de maladies par reactivation du thymus
US20060229251A1 (en) Treatment of T cell disorders
AU2001295270C1 (en) Treatment of T cell disorders
US20040265285A1 (en) Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20020119128A1 (en) Graft acceptance through manipulation of thymic regeneration
AU2001295270A1 (en) Treatment of T cell disorders
AU2002225245B2 (en) Improvement of graft acceptance through manipulation of thymic regeneration
US20020086003A1 (en) Stimulation of thymus for vaccination development
CA2462027A1 (fr) Stimulation du thymus pour ameliorer une vaccination
WO2002030257A2 (fr) Normalisation de la reactivite de lymphocytes t deficients par la manipulation de la regeneration thymique
US20040037817A1 (en) Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20040037816A1 (en) Graft acceptance through manipulation of thymic regeneration
ZA200303684B (en) Stimulation of thymus for vaccination development
AU2007202609A1 (en) Stimulation of thymus for vaccination development
AU2002225245A1 (en) Improvement of graft acceptance through manipulation of thymic regeneration

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued